IS6678A - Hvarfefni og prófanir fyrir ß-sekretasavirkni - Google Patents

Hvarfefni og prófanir fyrir ß-sekretasavirkni

Info

Publication number
IS6678A
IS6678A IS6678A IS6678A IS6678A IS 6678 A IS6678 A IS 6678A IS 6678 A IS6678 A IS 6678A IS 6678 A IS6678 A IS 6678A IS 6678 A IS6678 A IS 6678A
Authority
IS
Iceland
Prior art keywords
reagents
tests
secretory activity
substrates
asp
Prior art date
Application number
IS6678A
Other languages
English (en)
Inventor
Yan Riqian
G. Tomasselli Alfredo
E. Gurney Mark
L. Emmons Thomas
Jerome Bienkowski Michael
L. Heinrikson Robert
Original Assignee
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Company filed Critical Pharmacia & Upjohn Company
Publication of IS6678A publication Critical patent/IS6678A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS6678A 2000-07-19 2003-01-14 Hvarfefni og prófanir fyrir ß-sekretasavirkni IS6678A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21979500P 2000-07-19 2000-07-19
US27525101P 2001-03-12 2001-03-12
PCT/US2001/023035 WO2002006306A2 (en) 2000-07-19 2001-07-19 SUBSTRATES AND ASSAYS FOR β-SECRETASE ACTIVITY

Publications (1)

Publication Number Publication Date
IS6678A true IS6678A (is) 2003-01-14

Family

ID=26914256

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6678A IS6678A (is) 2000-07-19 2003-01-14 Hvarfefni og prófanir fyrir ß-sekretasavirkni

Country Status (11)

Country Link
US (8) US7205120B2 (is)
EP (1) EP1301604B1 (is)
JP (1) JP2004504018A (is)
AT (1) ATE397077T1 (is)
AU (1) AU2001277950A1 (is)
CA (1) CA2410898A1 (is)
DE (1) DE60134230D1 (is)
IL (1) IL153943A0 (is)
IS (1) IS6678A (is)
TW (2) TW200628612A (is)
WO (1) WO2002006306A2 (is)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19983100T1 (de) * 1998-04-06 2001-05-31 Imation Corp Herstellung eines umgekehrten optischen Masters für Datenspeicherplatten
US7196163B2 (en) 2001-05-22 2007-03-27 Merk & Co., Inc. Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity
TWI243826B (en) * 2001-07-19 2005-11-21 Akzo Nobel Nv Process for the preparation of peptides
TWI247012B (en) * 2001-07-19 2006-01-11 Akzo Nobel Nv Process for rapid solution synthesis of peptides
US20060068388A1 (en) * 2002-04-18 2006-03-30 Esbatech Ag Method for the identification of modulators of a secretase activity
JP2004000060A (ja) * 2002-05-31 2004-01-08 Otsuka Pharmaceut Co Ltd アミロイドβ産生に影響を与える化合物のスクリーニング方法
CA2505907A1 (en) * 2002-11-14 2004-06-03 Qtl Biosystems, Llc Methods of biosensing using fluorescent polymers and quencher-tether-ligand bioconjugates
US20050112696A1 (en) * 2003-11-25 2005-05-26 The University Of Texas Southwestern Medical Center Compositions, methods and assays related to secretase cleavage specificity
US20060098887A1 (en) * 2004-05-19 2006-05-11 Hazem El-Bakry Mehthod for image conversion
US20060223849A1 (en) * 2005-03-14 2006-10-05 Mjalli Adnan M Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
DE102005051978A1 (de) * 2005-10-31 2007-05-10 Forschungszentrum Borstel Zentrum für Medizin und Biowissenschaften Verfahren zur Bestimmung der Spaltbarkeit von Substraten
JP4848986B2 (ja) * 2007-03-22 2011-12-28 富士ゼロックス株式会社 光導波路及びその製造方法
US8548257B2 (en) * 2009-01-05 2013-10-01 Apple Inc. Distinguishing between faces and non-faces
WO2012064836A1 (en) 2010-11-10 2012-05-18 Genentech, Inc. Methods and compositions for neural disease immunotherapy
JP2013158281A (ja) * 2012-02-03 2013-08-19 Shionogi & Co Ltd 新規ｂａｃｅ１活性測定方法
JP6859259B2 (ja) 2014-11-19 2021-04-14 ジェネンテック， インコーポレイテッド ＢＡＣＥｌに対する抗体及び神経疾患免疫療法のためのその使用
WO2016081640A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
EP4056696A4 (en) * 2019-11-08 2023-11-22 Gwangju Institute of Science and Technology SYNTHETIC ALPHA SECRETASE AND USE THEREOF

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292652A (en) 1990-10-05 1994-03-08 Athena Neurosciences, Inc. Amyloidin protease and uses thereof
US5798224A (en) * 1992-12-29 1998-08-25 Doheny Eye Institute Nucleic acids encoding protocadherin
JP4052605B2 (ja) * 1994-05-18 2008-02-27 タカラバイオ株式会社 α−１，３／４−フコシダーゼ遺伝子
JPH11507538A (ja) * 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
US6803188B1 (en) * 1996-01-31 2004-10-12 The Regents Of The University Of California Tandem fluorescent protein constructs
GB9701684D0 (en) 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
WO1999040930A1 (en) * 1998-02-12 1999-08-19 Center For Blood Research, Inc. Specific inhibitors of nfat activation by calcineurin and their use in treating immune-related diseases
US7090976B2 (en) * 1999-11-10 2006-08-15 Rigel Pharmaceuticals, Inc. Methods and compositions comprising Renilla GFP
CA2330242A1 (fr) * 1998-06-05 1999-12-16 Aventis Pharma S.A. Polypeptides possedant une activite de type beta-secretase
ATE276754T1 (de) * 1998-07-21 2004-10-15 Cytovia Inc Neue fluoreszensfarbstoffe und ihre anwendung in fluoreszensnachweisverfahren ganzer zellen für kaspasen, peptidasen, proteasen und andere enzyme sowie deren verwendung
PL205294B1 (pl) 1998-09-24 2010-03-31 Upjohn Co Izolowany lub oczyszczony polipeptyd, oczyszczony lub izolowany polinukleotyd, wektor, wektor ekspresyjny, komórka gospodarza, sposób wytwarzania polipeptydu, sposoby identyfikowania czynnika obniżającego, modulującego lub hamującego aktywność, zastosowanie takiego czynnika, izolowany kwas nukleinowy, obejmujący go wektor i ich zastosowanie, sposoby zmniejszania komórkowego wytwarzania beta amyloidu i zastosowanie antysensownego reagenta
US6313268B1 (en) * 1998-10-16 2001-11-06 Vivian Y. H. Hook Secretases related to Alzheimer's dementia
GB2364059B (en) 1999-02-10 2004-01-14 Elan Pharm Inc Beta-Secretase enzyme compositions and methods
WO2000058479A1 (en) 1999-03-26 2000-10-05 Amgen Inc. Beta secretase genes and polypeptides
CA2374610A1 (en) * 1999-06-28 2001-01-04 Jordan J. N. Tang Catalytically active recombinant memapsin and methods of use thereof
US7429639B2 (en) * 1999-09-29 2008-09-30 Ludwig Institute For Cancer Research SSX-2 peptides presented by HLA class II molecules
GB9925136D0 (en) * 1999-10-22 1999-12-22 Smithkline Beecham Plc Novel treatment
EP1237930B1 (en) * 1999-12-08 2006-11-08 Intellect Neurosciences, Inc. Chimeric amyloid beta peptides
DE60124080T2 (de) * 2000-03-23 2007-03-01 Elan Pharmaceuticals, Inc., San Francisco Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
CA2448142A1 (en) 2001-05-22 2002-11-28 Merck & Co., Inc. Beta-secretase substrates and uses thereof

Also Published As

Publication number Publication date
US7205120B2 (en) 2007-04-17
TWI316960B (en) 2009-11-11
WO2002006306A3 (en) 2002-07-25
US20040241792A1 (en) 2004-12-02
AU2001277950A1 (en) 2002-01-30
EP1301604B1 (en) 2008-05-28
DE60134230D1 (de) 2008-07-10
US20030017991A1 (en) 2003-01-23
US20040254341A1 (en) 2004-12-16
US20080299596A1 (en) 2008-12-04
TW200628612A (en) 2006-08-16
US20080090260A1 (en) 2008-04-17
US20040254342A1 (en) 2004-12-16
US20040253706A1 (en) 2004-12-16
US20050096457A1 (en) 2005-05-05
JP2004504018A (ja) 2004-02-12
EP1301604A2 (en) 2003-04-16
US7888291B2 (en) 2011-02-15
ATE397077T1 (de) 2008-06-15
US7803739B2 (en) 2010-09-28
WO2002006306A2 (en) 2002-01-24
CA2410898A1 (en) 2002-01-24
IL153943A0 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
IS6678A (is) Hvarfefni og prófanir fyrir ß-sekretasavirkni
DE60144145D1 (de) Subtilisin-variante
DE60325892D1 (de) Stellungs- und verwendungsverfahren
ATE380822T1 (de) Funf-helix protein
IL150168A0 (en) Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods bsed thereon
DK1229047T3 (da) IL-1-receptor-fusionsproteiner anvendt som antagonister og fremgangsmåder til fremstilling og anvendelse
DK1259547T3 (da) Højpotente, rekombinante antistoffer og fremgangsmåde til fremstilling heraf
WO2003031464A3 (en) Remodeling and glycoconjugation of peptides
NZ521396A (en) Fusion proteins comprising two or more Neisseria polypeptides
DK0776331T3 (da) Struktur af højere orden og binding af peptidnukleinsyrer
ATE355368T1 (de) Nucleinsäure bindende polypeptide gekennzeichnet durch flexible linker verbundene nucleinsäuredomäne
DK1084146T3 (da) Hybridprotein til inhibering af degranuleringen af mastocyter og anvendelse deraf
ATE382148T1 (de) Antikörper für apoptosemarker und anwendungsverfahren
DK1346034T3 (da) von Willebrand-faktor (vWF) spaltende protease-polypeptid, nukleinsyre kodende for polypeptidet og anvendelse af polypeptidet
DK1532261T3 (da) Fremgangsmåder og DNA-konstrukter til produktion af polypeptider med højt udbytte
FR2831170B1 (fr) Proteines c modifiees activables directement par la thrombine
DK372086D0 (da) Fremgangsmaade til rekombinant-dna-syntese af en serinproteaseinhibitor og dna-sekvenser, som er nyttige derved
ATE501268T1 (de) Vorrichtungen und verfahren zur bestimmung von proteaseaktivität
DE69938130D1 (de) Neue peptide
DE60316718D1 (de) Lösliche notch basierte substrate für gamma secretase, methoden, zusammensetzungen und verwendungen davon
DK0994187T3 (da) Renin-aktivt stof omfattende humant prorenin og antistoffer mod prorenin-profragmentet
MXPA02012030A (es) Sustratos peptidicos de metalorpoteasas y metodos.
GB0221169D0 (en) Crystal
DK0769025T3 (da) Metoder og sammensætninger i relation til proteoglycanproteiner til diagnosticering af brusknedbrydning
SE0101519D0 (sv) Nucleic ACID